Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.

Prelaj A, Rebuzzi SE, Grassi M, Salvati M, D'Elia A, Buttarelli F, Ferrara C, Tomao S, Bianco V.

Mol Clin Oncol. 2019 Jan;10(1):58-66. doi: 10.3892/mco.2018.1746. Epub 2018 Oct 16.

2.

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy.

Prelaj A, Rebuzzi SE, Grassi M, Giròn Berrìos JR, Pecorari S, Fusto C, Ferrara C, Salvati M, Stati V, Tomao S, Bianco V.

Mol Clin Oncol. 2019 Jan;10(1):49-57. doi: 10.3892/mco.2018.1745. Epub 2018 Oct 16.

3.

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.

Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J.

Clin Transl Oncol. 2016 Aug;18(8):805-12. doi: 10.1007/s12094-015-1444-2. Epub 2015 Nov 5.

PMID:
26542177
4.

Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.

Lombardi G, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D'Avella D, Zagonel V.

J Neurooncol. 2016 Jul;128(3):481-6. doi: 10.1007/s11060-016-2136-7. Epub 2016 May 11.

PMID:
27165580
5.

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.

Fabi A, Metro G, Russillo M, Vidiri A, Carapella CM, Maschio M, Cognetti F, Jandolo B, Mirri MA, Sperduti I, Telera S, Carosi M, Pace A.

BMC Cancer. 2009 Mar 31;9:101. doi: 10.1186/1471-2407-9-101.

6.

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S.

J Neurooncol. 2011 May;102(3):417-24. doi: 10.1007/s11060-010-0329-z. Epub 2010 Aug 10. Erratum in: J Neurooncol. 2011 May;102(3):425. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

7.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

8.

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.

Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S.

J Neurooncol. 2013 Jul;113(3):397-401. doi: 10.1007/s11060-013-1125-3. Epub 2013 Apr 6.

9.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
10.

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.

Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A.

Br J Neurosurg. 2013 Dec;27(6):772-8. doi: 10.3109/02688697.2013.791664. Epub 2013 May 11.

PMID:
23662801
11.

Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.

Conde-Moreno AJ, García-Gómez R, Albert-Antequera M, Almendros-Blanco P, De Las Peñas-Bataller R, González-Vidal V, López-Torrecilla JL, Ferrer-Albiach C.

Rep Pract Oncol Radiother. 2015 May-Jun;20(3):231-8. doi: 10.1016/j.rpor.2015.01.004. Epub 2015 Feb 20.

12.

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.

Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A.

J Neurooncol. 2010 Nov;100(2):209-15. doi: 10.1007/s11060-010-0163-3. Epub 2010 Mar 30.

PMID:
20352471
13.

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).

Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R.

J Neurooncol. 2014 Feb;116(3):533-41. doi: 10.1007/s11060-013-1317-x. Epub 2013 Dec 1.

14.

Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.

Liu Z, Zhang G, Zhu L, Wang J, Liu D, Lian L, Liu J, Lai T, Zhuang X.

Biomed Res Int. 2015;2015:723612. doi: 10.1155/2015/723612. Epub 2015 Feb 18.

15.

A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.

Paccapelo A, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Santoni M, Bonizzoni E, Perrone T, Scoccianti S.

J Transl Med. 2012 May 14;10:90. doi: 10.1186/1479-5876-10-90.

16.

The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.

Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD.

Acta Neurochir (Wien). 2016 Oct;158(10):1943-53. doi: 10.1007/s00701-016-2928-8. Epub 2016 Aug 15.

PMID:
27526690
17.

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D.

J Clin Oncol. 2005 Dec 1;23(34):8863-9.

PMID:
16314646
18.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
19.

Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.

Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM.

J Neurooncol. 2015 May;122(3):559-66. doi: 10.1007/s11060-015-1745-x. Epub 2015 Feb 22.

PMID:
25702193
20.

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M.

Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75. doi: 10.1007/s00280-009-0926-8. Epub 2009 Jan 24.

Supplemental Content

Support Center